Recent advances with the CRF1 receptor: Design of small molecule inhibitors, receptor subtypes and clinical indications

Current Pharmaceutical Design

Volumn 5, Issue 5, 1999, Pages 289-315

  McCarthy, James R ^a   Heinrichs, Stephen C ^a   Grigoriadis, Dimitri E ^a  

^a NEUROCRINE BIOSCIENCES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 4 [N (CYCLOPROPYLMETHYL) N PROPYLAMINO] 2 METHYL 6 (2,4,6 TRICHLOROANILINO)PYRIMIDINE; ANTALARMIN; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR DERIVATIVE; CYCLIC AMP; RECEPTOR SUBTYPE; SAUVAGINE; UNCLASSIFIED DRUG; CORTICOTROPIN RELEASING FACTOR RECEPTOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADENOHYPOPHYSIS; ANXIETY NEUROSIS; ARTICLE; AUTORADIOGRAPHY; BLOOD BRAIN BARRIER; DEPRESSION; DNA SEQUENCE; DRUG STRUCTURE; HYPOPHYSIS CELL; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEPTOR AFFINITY; RECEPTOR BINDING; SUBSTANCE ABUSE; ADDICTION; ANIMAL; ANXIETY; CLASSIFICATION; DRUG ANTAGONISM; DRUG DESIGN; HUMAN; KINETICS; METABOLISM; REVIEW; SEIZURE;

ANIMALS; ANXIETY; DEPRESSION; DRUG DESIGN; HUMANS; KINETICS; PYRIMIDINES; PYRROLES; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SEIZURES; SUBSTANCE-RELATED DISORDERS;

EID: 0032586642     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (183)

1. Guillemin, R.; Rosenberg, B. Endocrinology 1955, 57, 599.
2. Saffran, M.; Schally, A.V.; Benfey, B.G. Endocrinology 1955, 57, 439.
3. Vale, W.; Spiess, J.; Rivier, C.; Rivier, J. Science 1981, 213, 1394.
4. Vaughan, J.; Donaldson, C.; Bittencourt, J.; Perrin, M.H.; Lewis, K.; Sutton, S.; Chan, R.; Turnbull, A.V.; Lovejoy, D.; Rivier, C.; Rivier, J.; Sawchenko, P.E.; Vale, W. Nature 1995, 378(6554), 287.
5. Romier, C.; Bernassau, J.-M.; Cambillau, C.; Darbon, H. Prot Eng 1993, 6(2), 149.
6. Rivier, J.; Rivier, C.; Vale, W. Science 1984, 224, 889.
7. Petrusz, P.; Merchenthaler, I. The corticotropin-releasing factor system, In, Neuroendocrinology, 1992 (Nemeroff, C.B., ed.), CRC Press, Inc., Boca Raton, FL, pp. 129.
8. Sawchenko, P.E.; Swanson, L.W. Organization of CRF immunoreactive cells and fibers in the rat brain, immunohistochemical studies, In, Corticotropin-releasing factor, Basic and clinical studies of a neuropeptide, 1990 (De Souza, E.B.; Nemeroff, C.B., eds.). CRC Press, Inc., Boca Raton, FL, pp. 29.
9. Swanson, L.W.; Sawchenko, P.E.; Rivier, J.; Vale, W.W. Neuroendocrinology 1983, 36, 165.
10. Owens, M.J.; Nemeroff, C.B. Pharmacol Rev 1991, 43(4), 425.
11. Theoharides, T.C.; Singh, L.K.; Boucher, W.; Pang, X.; Letourneau, R.; Webster, E.; Chrousos, G. Endocrinology 1998, 139(1), 403.
12. Singh, L.K.; Boucher, W.; Pang, X.; Letourneau, R.; Seretakis, D.; Green, M.; Theoharides, T.C. J Pharmacol Exp Ther 1999, 288(3), 1349.
13. Shibasaki, T.; Odagiri, E.; Shizume, K.; Ling, N. J Clin Endocrinol Metab 1982, 55, 384.
14. Lowry, P.J.; Woods, R.J.; Baigent, S. Pharmacol Biochem Behav 1996, 54(1), 305.
15. Di Blasio, A.M.; Giraldi, F.P.; Vigano, P.; Petraglia, F.; Vignali, M.; Cavagnini, F. J Clin Endocrinol Metab 1997, 82(5), 1594.
16. Aguilera, G.; Millan, M.A.; Hauger, R.L.; Catt, K.J. Corticotropin-releasing factor receptors, Distribution in brain, pituitary and peripheral tissues, In, The hypothalamic-Pituitary-Adrenal Axis Revisited, 1987 (Ganong, W.F.; Dallman, M.F.; Roberts, J.L., eds.). The New York Academy of Sciences, New York, pp. 48.
17. De Souza, E.B. J Neurosci 1987, 7, 88.
18. De Souza, E.B.; Kuhar, M.J. Meth Enzymol 1986, 124, 560.
19. De Souza, E.B. Corticotropin-releasing hormone receptors, In, Handbook of chemical Neuroanatomy - Neuropeptide receptors in the CNS, Part III, 1992 (Bjorklund, A.; Hokfelt, T.; Kuhar, M.J., eds.). Elsevier, Amsterdam, pp. 145.
20. Chang, C.P.; Pearse, R.I.; O'Connell, S.; Rosenfeld, M.G. Neuron 1993, 11(6), 1187.
21. Chen, R.; Lewis, K.A.; Perrin, M.H.; Vale, W.W. Proc Natl Acad Sci (USA) 1993, 90(19), 8967.
22. Perrin, M.H.; Donaldson, C.J.; Chen, R.; Lewis K.A.; Vale, W.W. Endocrinology 1993, 133(6), 3058.
23. Vita, N.; Laurent, P.; Lefort, S.; Chalon, P.; Lelias, J.M.; Kaghad, M.; Le, F.G.; Caput, D.; Ferrara, P. FEBS Lett 1993, 335(1), 1.
24. Lovenberg, T.W.; Liaw, C.W.; Grigoriadis, D.E.; Clevenger, W.; Chalmers, D.T.; De Souza, E.B.; Oltersdorf, T. Proc Natl Acad Sci (USA) 1995, 92, 836.
25. Kishimoto, T.; Pearse II, R.V.; Lin, C.R.; Rosenfeld, M.G. Proc Natl Acad Sci (USA) 1995, 92, 1108.
26. Perrin, M.; Donaldson, C.; Chen, R.; Blount, A.; Berggren, T.; Bilezikjian, L.; Sawchenko, P.; Vale, W. Proc Natl Acad Sci (USA) 1995, 92, 2969.
27. Kostich, W.; Chen, A.; Sperle, K.; Horlick, R.A.; Patterson, J.; Largent, B.L. Soc Neurosci Abstr 1996, 22(2), 1545.
28. Lovenberg, T.W.; Chalmers, D.T.; Liu, C.; De Souza, E.B. Endocrinology 1995, 136, 4139.
29. Grigoriadis, D.E.; Liaw, C.W.; Oltersdorf, T.; De Souza, E.B. Soc Neurosci Abstr 1994, 20, 1345.
30. Grigoriadis, D.E.; Liu, X.J.; Vaughn, J.; Palmer, S.F.; True, C.D.; Vale, W.W.; Ling, N.; De Souza, E.B. Mol Pharmacol 1996, 50, 679.
31. Chalmers, D.T.; Lovenberg, T.W.; De Souza, E.B. J Neurosci 1995, 15, 6340.
32. De France, J.F. The Septal Nuclei, ed., 1976, New York, Plenum.
33. Sakanaka, M.; Magari, S.; Shibasaki, T.; Lederis, K. J Comp Neurol 1988, 270, 404.
34. De Souza, E.B.; Grigoriadis, D.E. Corticotropin-releasing factor, Physiology, pharmacology and role in central nervous system and immune disorders, In, Psychopharmacology, The Fourth Generation of Progress, 1994 (Bloom, F.E.; Kupfer, D.J., eds.). Raven Press, New York, pp. 505.
35. De Souza, E.B.; Nemeroff, C.B. Corticotropin-releasing factor, Basic and clinical studies of a neuropeptide. CRC Press, Inc., Boca Raton, Florida, 365 (1990).
36. Grigoriadis, D.E.; Heroux, J.A.; De Souza, E.B. Characterization and regulation of corticotropin-releasing factor receptors in the central nervous, endocrine and immune systems, In, Corticotropin-Releasing Factor, 1993 (Chadwick, D.J.; Marsh, J.; Ackrill, K., eds.). John Wiley and Sons Ltd., Chichester, West Sussex, pp. 85.
37. Birnbaumer, L. Annu Rev Pharmacol Toxicol 1990, 30, 675.
38. Moreau, J.L.; Kilpatrick, G.; Jenck, F. Neuroreport 1997, 8(7), 1697.
39. Bremner, J.D.; Licinio, J.; Darnell, A.; Krystall, J.H.; Owens, M.J.; Southwick, S.M.; Nemeroff, C.B.; Charney, D.S. Am J Psychiatry 1997, 154(5), 624.
40. Yehuda, R.; Teicher, M.H.; Levengood, R.A.; Trestman, R.L.; Siever, L.J. Ann New York Acad Sci 1994, 746, 378.
41. Nemeroff, C.B. Biol Psychiatry 1998, 44(7), 517.
42. Nemeroff, C.B.; Owens, M.J.; Bissett, G.; Andorn, A.C.; Stanley, M. Arch Gen Psychiatry 1988, 45, 577.
43. Roy, A.; Pickar, D.; Paul, S.; Doran, A.; Chrousos, G.P.; Gold, P.W. Am J Psychiatry 1987, 143, 896.
44. Nemeroff, C.B.; Bissette, G.; Akil, H.; Fink, M. Br J Psychiat 1991, 158, 59.
45. Grigoriadis, D.E.; Pearsall, D.M.; De Souza, E.B. Neuropsychopharmacology 1989, 2, 53.
46. Valentino, R.J.; Foote, S.L.; Page, M.E. Ann New York Acad Sci 1993, 697, 173.
47. Chappell, P.B.; Smith, M.A.; Kilts, C.D.; Bissette, G.; Ritchie, J.; Anderson, C.; Nemeroff, C.B. J Neurosci 1986, 6, 2908.
48. Valentino, R.J.; Foote, S.L.; Aston, J.G. Brain Res 1990, 270(363), 363.
49. Koob, G.F.; Heinrichs, S.C.; Menzaghi, F.; Merlo Pich, E.; Britton, K.T. Seminars in Neuroscience 1994, 6, 221.
50. Roy-Byrne, P.P.; Uhde, T.; Post, R.; Gallucci, W.; Chrousos, G.P.; Gold, P.W. Am J Psychiatry 1986, 143, 896.
51. Jones, D.N.; Kortikaas, R.; Slade, P.D.; Middlemiss, D.N.; Hagan, J.J. Psychopharmacol 1998, 138(2), 124.
52. Smith, M.A.; Weiss, S.R.B.; Berry, R.L.; Zhang, L.-X.; Clark, M.; Massenburg, G.; Post, R.M. Brain Res 1997, 745, 248.
53. APA. Diagnostic and Statistical Manual of Mental Disorders -Fourth Edition. (DSM-IV), ed., 1994, Washington DC, American Psychiatric Association.
54. Owens, M.J.; Vargas, M.A.; Knight, D.L.; Nemeroff, C.B. J Pharmacol Exp Ther 1991, 258, 349.
55. Calogero, A.E. Ann N Y Acad Sci 1995, 771, 31.
56. Sarnyai, Z.; Bíró, É.; Penke, B.; Telegdy, G. Brain Res 1992, 589, 154.
57. Rivier, C.; Vale, W. Brain Res 1987, 422, 403.
58. Fischman, M.W.; Schuster, C.R.; Hatano, Y. Pharmacol Biochem Behav 1983, 18(123), 123.
59. Teoh, S.K.; Sarnyai, Z.; Mendelson, J.H.; Mello, N.K.; Springer, S.A.; Sholar, J.W.; Wapler, M.; Kuehnle, J.C.; Gelles, H. J Pharmacol Exp Ther 1994, 270(3), 1134.
60. Berger, S.P.; Hall, S.; Mickalian, J.D.; Reid, M.S.; Crawford, C.A.; Delucchi, K.; Carr, K.; Hall, S. Lancet 1996, 347, 504.
61. Piazza, P.V.; Le Moal, M. Annual Reviews of Pharmacology and Toxicology 1996, 36, 359.
62. Shaham, Y.; Leung, S.; Buczek, Y.; J. S. Psychopharmacol 1998, 137(2), 184.
63. Zhou, Y.; Spangler, R.; LaForge, K.S.; Maggos, C.E.; Ho, A.; Kreek, M.J. J Pharmacol Exp Ther 1996, 279(1), 351.
64. Yang, X.-M.; Gorman, A.L.; Dunn, A.J.; Goeders, N.E. Pharmacol Biochem Behav 1992, 41, 643.
65. Shaham, Y.; Rajabi, H.; Stewart, J. J Neurosci 1996, 16(5), 1957.
66. Goeders, N.E.; Guerin, G.F. Psychopharmacol 1994, 114, 63.
67. Koob, G.F. Neuron 1996, 16, 893.
68. Gawin, F.H.; Kleber, H.D. Arch Gen Psychiatry 1986, 43, 107.
69. Cooney, N.L.; Litt, M.D.; Morse, P.A.; Bauer, L.O.; Gaupp, L. Journal of Abnormal Psychology 1997, 106(2), 243.
70. Brown, S.A.; Vik, P.W.; McQuaid, J.R.; Patterson, T.L.; Irwin, M.R.; Grant, I. Journal of Abnormal Psychology 1990, 99(4), 344.
71. Childress, A.R.; Ehrman, R.; McLellan, A.T.; MacRae, J.; Natale, M.; O'Brien, C.P. Journal of Substance Abuse Treatment 1994, 11(1), 17.
72. Litt, M.D.; Cooney, N.L.; Kadden, R.M.; Gaupp, L. Addictive Behaviors 1990, 15(2), 137.
73. Tiffany, S.T.; Drobes, D.J. Addictive Behaviors 1990, 15(6), 531.
74. Stenzel-Poore, M.P.; Duncan, J.E.; Rittenberg, M.B.; Bakke, A.C.; Heinrichs, S.C. Ann N Y Acad Sci 1996, 780, 36.
75. Stenzel-Poore, M.P.; Heinrichs, S.C.; Rivest, S.; Koob, G.F.; Vale, W.W. The journal of neuroscience 1994, 14, 2579.
76. Heinrichs, S.C.; Stenzel-Poore, M.P.; Gold, L.H.; Battenberg, E.; Bloom, F.E.; Koob, G.F.; Vale, W.W.; Merlo Pich, E. Neuroscience 1996, 74(2), 303.
77. Heinrichs, S.C.; Min, H.; Tamraz, S.; Carmouché, M.; Boehme, S.; Vale, W.W. Psychoneuroendocrinology 1997,.22(4), 215.
78. Lovenberg, T.W.; Grigoriadis, D.E.; Chalmers, D.T.; McCarthy, J.R.; De Souza, E.B. Current Pharmaceutical Design 1995, 1, 305.
79. Chen, C.; Dagnino Jr., R.; De Souza, E.B.; Grigoriadis, D.E.; Huang, C.Q.; Kim, K.I.; Lui, Z.; Moran, T.; Webb, T.R.; Whitten, J.P.; Xie, Y.F.; McCarthy, J.R. J Med Chem 1996, 39, 4358.
80. Hodge, C.N.; Aldrich, P.E.; Fernandez, C.; Chorvat, R.J.; Cheesman, R.S.; Christos, T.E.; Arvanitis, A.G.; Scholfield, E.; Krenitsky, P.J.; Gilligan, P.J.; Ciganek, E.; Strucely, P.; Wasserman, Z.R. Anilinopyrimidines as corticotropin-releasing hormone (CRH) antagonists, in 212 ACS National Meeting. American Chemical Society, Orlando FL, MEDI 094 (1996).
81. Abreu, M.E.; Rzeszotarski, W.; Kyle, D.J.; Elliot, R.L. Corticotropin-releasing factor antagonism compounds, 1991, US 5,063,245.
82. Courtemanche, G.; Gautier, C.; Gully, D.; Roger, P.; Valette, G.; Wermuth, C.G. Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent, 1993, EP 0 576 350 A1.
83. McCarthy, J.R.; Whitten, J.P.; Webb, T.R.; Ramphal, J.Y.; Grigoriadis, D.E.; Chen, C.; Huang, C.Q.; Liu, Z.; Xie, Y.F.; Dagnino, R. Amino-substituted thiadiazoles, pyrimidines, triazines or triazoles useful as CRF receptor antagonists, 1996, WO 96/39400.
84. McCarthy, J.R.; Chen, C.; De Souza, E.B.; Erickson, P.E.; Grigoriadis, D.E.; Webb, T.R.; Whitten, J.P.; Xie, Y.F. Design and synthesis of potent and selective CRF1 receptor antagonists with the aid of rapid microscale synthesis, in 212 ACS National Meeting. American Chemical Society, Orlando FL, MEDI 196 (1996).
85. Carpino, L.A.; H.-G., C.; Ghassemi, S.; Mansour, E.M.E.; Reimer, C.; Warrass, R.; Sadat-Aalaee, D.; Truran, G.A.; Imazumi, H.; El-Faham, A.; Ionescu, D.; Ismail, M.; Kowaleski, T.L.; Han, C.H. Journal of Organic Chemistry 1995, 60, 7718.
86. Whitten, J.P.; Xie, Y.F.; Erickson, P.E.; Webb, T.R.; De Souza, E.B.; Grgoriadis, D.E.; McCarthy, J.R. J Med Chem 1996, 39, 4354.
87. Gully, D.; Roger, P.; Wermuth, C.G. 4-phenylaminothiazole derivatives, method for preparing same and pharmaceutical compositions containing said derivatives., 1997, WO 97/00868.
88. Chen, Y.L. Corticotropin releasing factor antagonists, 1995, WO 95/33750.
89. Aldrich, P.E.; Arvanitis, A.G.; Cheeseman, R.S.; Chorvat, R.J.; Christos, T.E.; Gilligan, P.J.; Grigoriadis, D.E.; Hodge, C.N.; Krenitsky, P.J.; Scholfield, E.L.; Tam, S.W.; Wasserman, Z.R. IN-Alkyl-N-arylpyrimidinamines and derivatives thereof, 1995, WO 95/10506.
90. Chen, C.; Dagnino, J., R.; McCarthy, J.R. Journal of Organic Chemistry 1995, 60, 8428.
91. Arvanitis, A.G.; Aldrich, P.E.; Arnold, C.R.; Bakthavatchalam, R.; Beck, J.P.; Bouchard, P.J.; Cheesman, R.S.; Chidester, D.R.; Chorvat, R.J.; Christos, T.E.; Cocuzza, A.J.; Culp, S.J.; Curry, M.; Fitzgerald, L.W.; Gilligan, P.J.; Hartig, P.R.; He, L.; Hobbs, F.W.; Hodge, C.N.; Krenitsky, P.J.; McCall, D.E.; Rescinito, J.T.; Scholfield, E.L.; Tam, S.W.; Trainor, G.L.; Wasserman, Z.R.; Wilde, J.A.; Yarem, J.A.; Zaczek, R. Anilinopyrimidines as corticotropin-releasing hormone (CRH) antagonists, in 212 ACS National Meeting. American Chemical Society, Orlando FL, MEDI 194 (1996).
92. Christos, T.E.; Arvanitis, A.G.; Beck, J.P.; Cheesman, R.S.; Chorvat, R.J.; Cocuzza, A.J.; Culp, S.J.; Gilligan, P.J.; Hartig, P.R.; Hobbs, F.W.; Klaczkiewicz, J.; Krenitsky, P.J.; Scholfield, E.L.; Wilde, J.A.; Zaczek, R. Anilinopyrimidines as corticotropin-releasing hormone (CRH) antagonists, in 212 ACS National Meeting. American Chemical Society, Orlando FL, MEDI 092 (1996).
93. Bakthavatchalam, R.; Aldrich, P.E.; Arvanitis, A.G.; Beck, J.P.; Calabrese, J.C.; Cheesman, R.S.; Chorvat, R.J.; Christos, T.E.; Cocuzza, A.J.; Culp, S.J.; Curry, M.; Fitzgerald, L.W.; Gilligan, P.J.; Hobbs, F.W.; Hodge, C.N.; Huang, S.-M.; Krenitsky, P.J.; McCall, D.E.; Rescinito, J.T.; Wasserman, Z.R.; Wilde, J.A.; Wong, N.Y.; Yarem, J.A.; Zaczek, R. Anilinopyrimidines as corticotropin-releasing hormone (CRH) antagonists, in 212 ACS National Meeting. American Chemical Society, Orlando FL, MEDI 093 (1996).
94. Chen, Y.L.; Fossa, A.A. New Uses for corticotropin releasing factor (CRF) antagonists, 1997, EP 0 773 023 A1.
95. Bright, G.M. Amino-substituted pyrazoles having CRF antagonist activity, 1994, WO 94/13644.
96. Bright, G.M.; Welch, W.M.J. Substituted pyrazoles as CRF antagonists, 1994, WO 94/13661.
97. Faraci, W.S.; Welch, W.M.J. Pyrazoles and pyrazolopyrimidines having CRF antagonist activity., 1994, WO 94/13643.
98. De Souza, E.B.; Lovenberg, T.W.; Chalmers, D.T.; Grigoriadis, D.E.; Liaw, C.W.; Behan, D.P.; McCarthy, J.R. Annual Reports in Medicinal Chemistry 1995, 30, 21.
99. Schulz, D.W.; Mansbach, R.S.; Sprouse, J.; Braselton, J.P.; Collins, J.; M., C.; Dunaiskis, A.; Faraci, S.; Schmidt, A.W.; Seeger, T.; Seymour, P.; Tingley III, F.D.; Winston, E.N.; Chen, Y.L.; Heym, J. Proceedings of the National Academy of Sciences USA 1996, 93, 10477.
100. Chen, Y.L.; Mansbach, R.S.; Winter, S.M.; Brooks, E.; Collins, J.; Corman, M.L.; Dunaiskis, A.R.; Faraci, W.S.; Gallaschun, R.J.; Schmidt, A.; Schulz, D.W. J Med Chem 1997, 40(11), 1749.
101. Webster, E.L.; Lewis, D.B.; Torpy, D.J.; Zachman, E.K.; Rice, K.C.; Chrousos, G.P. Endocrinology 1996, 137(12), 5747.
102. Yuan, J.; Hutchinson, A. Deazapurine derivatives, a new class of CRF1 specific ligands, 1997, US 5,644,057.
103. Chen, C.; Webb, T.R.; McCarthy, J.R.; Wilcoxen, K.M. Pyrazolopyrimidines as CRF receptor antagonists, 1997, WO 97/29109.
104. Chen, C.; Webb, T.R.; McCarthy, J.R.; Moran, T.J. Thiophenopyrimidines, 1997, WO 97/29110.
105. Arvanitis, A.C.; Chorvat, R.J. Azolo triazines and pyrimidines, 1998, WO 98/03510.
106. Chen, Y.L. Substituted 6,5-hetero-bicyclic derivatives, 1998, WO 98/08847.
107. Wustrow, D.J.; Capiris, T.; Rubin, R.; Knobelsdorf, J.A.; Akunne, H.; Davis, M.D.; MacKenzie, R.; Pugsley, T.A.; Zoski, K.T.; Heffner, T.G.; Wise, L.D. Bioorg Med Chem Lett 1998, 8(16), 2067.
108. Gilligan, P.J.; Baldauf, C.; Cocuzza, A.; Chidester, D.; Fitzgerald, L.; Zaczek, R.; Shen, H. Pyrazolo[1,5-a]-pyrimidine CRF antagonists, Synthesis and structure activity., in 216 ACS National Meeting. American Chemical Society, Boston, MA, 135 (1998).
109. Capiris, T.; Wustrow, D.J.; Rubin, M.R.; Knobelsdorf, J.A.; Akunne, H.; Davis, M.D.; MacKenzie, R.; Pugsley, T.A.; Zoski, K.T.; Heffner, T.G.; Wise, L.D. Pyrazolo[1,5-a]pyrimidineCRF-1 receptor antagonists, in 26th National Medicinal Chemistry Symposium, Omni Richmond Hotel, Richmond VA, D (1998).
110. 1) receptor antagonists, in 217 ACS National Meeting, Anaheim, CA, MEDI 02 (1999).
111. Beck, J.P.; Arvanitis, A.G.; Cocuzza, A.J.; Chidester, D.R.; Curry, M.A.; Rescinito, J.T.; Fitzgerald, L.W.; Zaczek, R.; Calabrese, J.C. 8-oxopurines as CRH receptor antagonists, in 214 ACS National Meeting. American Chemical Society, Las Vegas, NV, MEDI 094 (1997).
112. Beck, J.P.; Curry, M.A.; Folmer, B.K.; Gilligan, P.J.; Robertson, D.W.; Fitzgerald, L.W.; Zaczek, R.; Calabrese, J.C. Thiazolo[4,5-d]pyrimidinethiones and -ones as potent corticotropin-releasing hormone (CRH-R1) receptor antagonists, in 216 ACS National Meeting. American Chemical Society, Boston, MA, 136 (1998).
113. Bakthavatchalam, R.; Arvanitis, A.G.; Gilligan, P.J.; Olson, R.E.; Robertson, D.W.; Trainor, G.L.; Smith, S.C.; Fitzgerald, L.W.; Zaczek, R.; Shen, H.; Christ, D.D. The discovery of DMP 695, an orally active corticotropin-releasing hormone (CRH1) receptor antagonist., in 216 ACS National Meeting. American Chemical Society, Boston, MA, 134 (1998).
114. Nakazato, A.; Okubo, T.; Kumagai, T.; Chaki, S.; Okuyama, S.; Tomisawa, K. Aryl-1,2,3,6-tetrahydropyridinopyrimidine derivatives as CRF1 receptor antagonists, in 216 ACS National Meeting. American Chemical Society, Boston, MA, 137 (1998).
115. Griebel, G.; Perrault, G.; Sanger, D.J. Psychopharmacol 1998, 138(1), 55.
116. Sutton, R.E.; Koob, G.F.; Le Moal, M.; Rivier, J.; Vale, W. Nature 1982, 297, 331.
117. Koob, G.F.; Swerdlow, N.; Seelingson, M. Neuroendocrinology 1984, 39, 459.
118. Sherman, J.E.; Kalin, N.H. Pharmacol Biochem Behav 1987, 26, 699.
119. Eaves, M.; Thatcher, B.K.; Rivier, J.; Vale, W.; Koob, G.F. Peptides 1985, 6(5), 923.
120. Britton, D.R.; Varela, M.; Garcia, A.; Rosenthal, M. Life Sci 1986, 38, 211.
121. Britton, K.T.; Lee, G.; Dana, R.; Risch, S.C.; Koob, G.F. Life Sci 1986, 39, 1281.
122. Takahashi, L.K.; Kalin, N.H.; Vandenburgt, J.A.; Sherman, J.E. Behavioral Neurosciences 1989, 103, 648.
123. Britton, D.R.; Koob, G.F.; Rivier, J.; Vale, W. Life Sci 1982, 31, 363.
124. Berridge, C.W.; Dunn, A.J. Regul Peptides 1986, 16, 83.
125. Baldwin, H.A.; Rassnick, S.; Rivier, J.; Koob, G.F.; Britton, K.T. Psychopharmacol 1991, 103, 227.
126. Britton, K.; Morgan, J.; Rivier, J.; Vale, W.; Koob, G.F. Psychopharmacol 1985, 86, 170.
127. Dunn, A.J.; File, S.E. Horm Behav 1987, 21, 193.
128. Swerdlow, N.R.; Geyer, M.A.; Vale, W.W.; Koob, G.F. Psychopharmacol 1986, 88, 147.
129. Cole, B.J.; Koob, G.F. J Pharmacol Exp Ther 1988, 247, 902.
130. Sherman, J.E.; Kalin, N.E. Pharmacol Biochem Behav 1988, 30, 801.
131. Dunn, A.J.; Berridge, C.W. Br Res Rev 1990, 15, 71.
132. Krahn, D.D.; Gosnell, B.A.; Grace, M.; Levine, A.S. Brain Res Bull 1986, 17, 285.
133. Tazi, A.; Dantzer, R.; Le Moal, M.; Rivier, J.; Vale, W.; Koob, G.F. Regul Peptides 1987, 18, 37.
134. Berridge, C.W.; Dunn, A.J. Horm Behav 1987, 21, 393.
135. Heinrichs, S.C.; Merlo Pich, E.; Miczek, K.A.; Britton, K.T.; Koob, G.F. Brain Res 1992, 581, 190.
136. Chalmers, D.T.; Lovenberg, T.W.; Grigoriadis, D.E.; Behan, D.P.; De Souza, E.B. Trends Pharmacol Sci 1996, 17, 166.
137. Vaughan, J.; Donaldson, C.; Bittencourt, J.; Lewis, K.; Lovejoy, D.; Black, J.; Rivier, J.; Sawchenko, P.; Vale, W. Characterization of a novel neuropeptide in rat brain related to CRF, in 25 th Annual Meeting Of The Neuroscience Society, San Diego (1995).
138. Liebsch, G.; Landgraf, R.; Gerstberger, R.; Probst, J.C.; Wotjak, C.T.; Engelmann, M.; Holsboer, F.; Montkowski, A. Regul Peptides 1995, 59, 229.
139. Behan, D.P.; Heinrichs, S.C.; Troncoso, J.C.; Liu, X.J.; Kawas, C.H.; Ling, N.; De Souza, E.B. Nature 1995, 378, 284.
140. Phillips, M.I.; Gyurko, R. Regul Peptides 1995, 59, 131.
141. Heinrichs, S.C.; Lapsansky, J.; Lovenberg, T.W.; De Souza, E.B.; Chalmers, D.T. Regulatory Peptidest 1997, 71(1), 15.
142. Mansbach, R.S.; Brooks, E.N.; Chen, Y.L. Eur J Pharmacol 1997, 323(1), 21.
143. Lundkvist, J.; Chai, Z.; Teheranian, R.; Hasanvan, H.; Bartfai, T.; Jenck, F.; Widmer, U.; Moreau, J.-L. Eur J Pharmacol 1996, 309, 195.
144. Arai, K.; Ohata, H.; Shibasaki, T. Neurosci Lett 1998, 25(2), 103.
145. Iredale, P.; Alvaro, J.; Lee, Y.; Terwilliger, R.; Chen, Y.; Duman, R. Soc. Neurosci. Abst. 1999, 23, 529.
146. Timpl, P.; Spanagel, R.; Sillaber, I.; Kress, A.; Reul, J.M.; Stalla, G.K.; Blanquet, V.; Steckler, T.; Holsboer, F.; Wurst, W. Nature Genetics 1998, 19(2), 162.
147. Baram, T.Z.; Hatalski, C.G. Trends in Neurosciences 1998, 21(11), 471.
148. Webster, E.L.; Torpy, D.J.; Elenkov, I.J.; Chrousos, G.P. Ann New York Acad Sci 1998, 840, 21.
149. Chan, E.C.; Falconer, J.; Madsen, G.; Rice, K.C.; Webster, E.L.; Chrousos, G.P.; Smith, R. Endocrinology 1998, 139(7), 3357.
150. Smagin, G.N.; Howell, L.A.; Ryan, D.H.; De Souza, E.B.; Harris, R.B. Neuroreport 1998, 9(7), 1601.
151. Bornstein, S.R.; Webster, E.L.; Torpy, D.J.; Richman, S.J.; Mitsiades, N.; Igel, M.; Lewis, D.B.; Rice, K.C.; Joost, H.G.; Tokos, M.; Chrousos, G.P. Endocrinology 1998, 139(4), 1546.
152. Rodriguez de Fonseca, F.; Carrera, M.R.A.; Navarro, M.; Koob, G.F.; Weiss, F. Science 1997, 276, 2050.
153. Chen, Y.L. Pyrrolopyrimidines as CRF antagonists, 1994, WO 94/13676.
154. Chen, Y.L. Pyrazolopyrimidines as CRF antagonists, 1994, WO 94/13677.
155. Bright, G.M.; Welch, W.M.J. Substituted pyrazoles having corticotropin-releasing factor (CRF) antagonist activity, 1995, WO 95/33727.
156. Chen, Y.L. Pyrazolo and pyrrolopyridines, 1995, WO 95/34563.
157. Chen, Y.L. Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders, 1996, EP 0 729 758 A2.
158. McCarthy, J.R.; Xie, Y.F.; Whitten, J.P.; Webb, T.R.; Chen, C.; Ramphal, J.Y. CRF receptor antagonists and methods relating thereto., 1998, US 5,795,905.
159. Volkmann, R.A. Benzimidazole derivatives and their use as corticotropin releasing factor antagonists, 1997, EP 0 812 831 A1.
160. Chen, Y.L. Substituted heterocyclic derivatives as CRF antagonists, 1997, EP 0 778 277 A1.
161. Webb, T.R.; Moran, T.J.; McCarthy, J.R. Amino substituted pyrimidines and triazines, 1997, WO 97/14684.
162. Bakthavatchalam, R.; Arvanitis, A.G.; Beck, J.P.; Cain, G.A.; Chorvat, R.J.; Gilligan, P.J. Arylamino fused pyridines and pyrimidines, 1997, WO 97/35539.
163. Chorvat, R.J.; Rajagopalan, P. Aryloxy-and arylthiosubstituted pyrimidines and triazines and derivatives thereof, 1997, WO 97/35580.
164. Rajagopalan, P.; Chorvat, R.J.; Bakthavatchalam, R.; Beck, J.P.; Gilligan, P.J.; Olson, R.E. Aryloxy-and arylthio-fused pyridines and pyrimidines and derivatives, 1997, WO 97/35846.
165. Wilde, R.G. Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders, 1997, WO 97/44038.
166. Yuan, J. 3-aryl substituted pyrazolo(4,3-D) pyrimidine derivatives; corticotropin-releasing factor (CRF1) specific ligands., 1998, US 5,723,608.
167. Chen, Y.L. Substituted pyrido-or pyrimido-containing 6,6-or 6,7-bicyclic derivatives, 1998, WO 98/05661.
168. Rabinovich, A.K.; Dhanoa, D.S.; Luthin, D.; Bychowski, R.A.; Bhumralkar, D.R. Benzoperimidine-carboxylic acids and derivatives thereof, 1998, WO 98/08821.
169. Rabinovich, A.K.; Dhanoa, D.S.; Luthin, D.R.; Bychowski, R.A.; Bhumralkar, D.R. Benzoperimidine-carboxylic acids and derivatives thereof., 1999, US 5,861,398.
170. Chen, Y.L. Substituted 6,6-hetero-bicyclic derivatives, 1998, WO 98/08846.
171. Arvanitis, A.G.; Olson, R.E.; Arnold, C.R.; Frietze, W.E. Pyrazinones and triazinones and their derivatives thereof., 1998, WO 98/11075.
172. Fontaine, E.; Gully, D.; Roger, P.; Wermuth, C.G. Aminothiazole derivatives, method of preparation and pharmaceutical compositions containing same., 1998, WO 98/15543.
173. Yuan, J. Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands, 1998, WO 98/21200.
174. Yuan, J.; Yoon, T. Isoquinolinamine and phthalazinamine derivatives which interact with CRF receptors., 1998, WO 98/27066.
175. Tanaka, H.; Seio, K.; Kimura, K.; Minoguchi, M.; Uchata, M.; Kohara, T.; Ohashi, Y.; Morio, Y.; Yamagami, K. Fused pyrimidine compounds and medicinal use thereof., 1998, WO 98/29397.
176. Nakazato, A.; Kumagai, T.; Okubo, T.; Aibe, I.; Tanaka, H.; Chaki, S.; Okuyama, S.; Tomisawa, K. 4-Tetrahydropyridylpyrimidine derivatives, 1998, WO 98/42699.
177. Horvath, R.F.; Hutchinson, A. Certain pyrrolopyridine derivatives; novel CRF1 specific ligands, 1998, WO 98/45295.
178. Huang, C.; Wilcoxen, K.M.; Chen, C.; McCarthy, J.R. CRF antagonistic quino-and quinazolines, 1998, WO 98/47874.
179. Webb, T.R.; McCarthy, J.R. CKF antagonistic thiophenopyrimidines, 1998, WO 98/47903.
180. Cocuzza, A.J.; Hobbs, F.W.; Beck, J.P.; Gilligan, P.J. Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists, 1999, WO 99/01439.
181. Wilde, R.G.; Bakthavatchalam, R.; Beck, J.P.; Arvanitis, A.G. Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders. 1999, WO 99/01454.
182. Adinoff, B.; Anton, R.; Linnoila, M.; Guidotti, A.; Nemeroft, C.B.; Bissette, G. Neuropsychopharmacology 1996, 15(3), 288.
183. Baram, T.Z.; Chalmers, D.T.; Chen, C.; Koutsoukos, Y.; De Souza, E.B. Brain Res 1997, 770(1-2), 89.